

Development of the First-in-class Drug for Sarcopenia

Aliad Biopharma Inc.



OTHERS	Lead
Product Type	Small molecules
Indication	Sarcopenia
Target	mTORC2
MoA(Mechanism of Action)	mTORC2 protein-protein interaction (PPI) inhibitor
Competitiveness	<ul style="list-style-type: none"> • Selective mTORC2 inhibitor • Subcellular compartment(endosome)-selective mTORC2 inhibitor • Increase the expression of α-Klotho • Increase the size of muscle fibers in old mice • Improve muscle strength and mobility in old mice
Development Stage	Lead
Route of Administration	PO

Any unauthorized distribution or reproduction of this material is strictly prohibited.